The estimated Net Worth of Phaedra Chrousos is at least 649 千$ dollars as of 14 June 2021. Ms. Chrousos owns over 2,075 units of Vanda Pharmaceuticals Inc stock worth over 63,591$ and over the last 6 years she sold VNDA stock worth over 40,131$. In addition, she makes 545,623$ as Independent Director at Vanda Pharmaceuticals Inc.
Phaedra has made over 1 trades of the Vanda Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she sold 2,075 units of VNDA stock worth 40,131$ on 14 June 2021.
The largest trade she's ever made was selling 2,075 units of Vanda Pharmaceuticals Inc stock on 14 June 2021 worth over 40,131$. On average, Phaedra trades about 259 units every 0 days since 2019. As of 14 June 2021 she still owns at least 12,925 units of Vanda Pharmaceuticals Inc stock.
You can see the complete history of Ms. Chrousos stock trades at the bottom of the page.
Phaedra Chrousos is Independent Director of the Company. Ms. Chrousos has served since November 2018 as the Chief Strategy Officer of The Libra Group, where she leads a wide range of strategic initiatives spanning technology transformation to operational development. Headquartered in New York and London, The Libra Group is a diverse, international business group that is active in 35 countries and focused on six business areas: aviation, energy, hospitality, real estate, shipping and diversified investments. Immediately prior to being appointed Chief Strategy Officer, Ms. Chrousos served as the group’s Chief Innovation Officer from October 2016 to October 2018. Previously, Ms. Chrousos served as a political appointee for the Obama Administration from June 2014 to July 2016 in various roles, including as an Associate Administrator for the General Services Administration. In this capacity, Ms. Chrousos led the Office of Citizen Services and 18F, a digital services team that implemented online service delivery projects and open data initiatives at more than a dozen agencies, including NIH, HHS and the VA. Prior to her departure from the Administration, Ms. Chrousos helped found the Technology Transformation Service, which serves as a foundation for the government’s ongoing digital transformation; she served as its Founding Commissioner. Prior to entering public service, Ms. Chrousos co-founded and led two companies, including HealthLeap, a health tech company that reimagined the way doctors and patients communicate. HealthLeap was acquired by Vitals.com 10 months after its launch. Ms. Chrousos served as HealthLeap’s President from September 2009 to December 2010 and Vitals.com’s Vice President responsible for HealthLeap from December 2010 to November 2011. She also has several years of consulting experience with The Boston Consulting Group and The World Bank.
As the Independent Director of Vanda Pharmaceuticals Inc, the total compensation of Phaedra Chrousos at Vanda Pharmaceuticals Inc is 545,623$. There are 8 executives at Vanda Pharmaceuticals Inc getting paid more, with Mihael Polymeropoulos having the highest compensation of 4,278,140$.
Phaedra Chrousos is 40, she's been the Independent Director of Vanda Pharmaceuticals Inc since 2019. There are 13 older and 2 younger executives at Vanda Pharmaceuticals Inc. The oldest executive at Vanda Pharmaceuticals Inc is Richard Dugan, 78, who is the Independent Director.
Phaedra's mailing address filed with the SEC is C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON, DC, 20037.
Over the last 19 years, insiders at Vanda Pharmaceuticals Inc have traded over 267,060,716$ worth of Vanda Pharmaceuticals Inc stock and bought 5,567,934 units worth 25,606,507$ . The most active insiders traders include Kevin Ctang Capital Managem...、Nicole Vitullo、Jesse I Treu. On average, Vanda Pharmaceuticals Inc executives and independent directors trade stock every 31 days with the average trade being worth of 546,607$. The most recent stock trade was executed by Kevin Patrick Moran on 29 July 2024, trading 2,251 units of VNDA stock currently worth 13,326$.
vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.
Vanda Pharmaceuticals Inc executives and other stock owners filed with the SEC include: